MedTrace Logo

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

NCT00961532 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-08-28

Study results available
· View outcomes & findings →

Summary

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Conditions

  • Intracerebral Hemorrhage

Interventions

DRUG

DDAVP injection (desmopressin acetate)

0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes

Sponsors & Collaborators

Principal Investigators

  • Andrew M Naidech, MD MSPH · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00961532 on ClinicalTrials.gov